Last reviewed · How we verify
Fispemifene once daily for 4 weeks — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Fispemifene once daily for 4 weeks (Fispemifene once daily for 4 weeks) — QuatRx Pharmaceuticals Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fispemifene once daily for 4 weeks TARGET | Fispemifene once daily for 4 weeks | QuatRx Pharmaceuticals Company | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fispemifene once daily for 4 weeks CI watch — RSS
- Fispemifene once daily for 4 weeks CI watch — Atom
- Fispemifene once daily for 4 weeks CI watch — JSON
- Fispemifene once daily for 4 weeks alone — RSS
Cite this brief
Drug Landscape (2026). Fispemifene once daily for 4 weeks — Competitive Intelligence Brief. https://druglandscape.com/ci/fispemifene-once-daily-for-4-weeks. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab